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Abstract
Background: Global malaria control strategies highlight the need to increase early uptake of effective antimalarials for
childhood fevers in endemic settings, based on a presumptive diagnosis of malaria in this age group. Many control
programmes identify private medicine sellers as important targets to promote effective early treatment, based on
reported widespread inadequate childhood fever treatment practices involving the retail sector. Data on adult use of
over-the-counter (OTC) medicines is limited. This study aimed to assess childhood and adult patterns of OTC medicine
use to inform national medicine retailer programmes in Kenya and other similar settings.
Methods: Large-scale cluster randomized surveys of treatment seeking practices and malaria parasite prevalence were
conducted for recent fevers in children under five years and recent acute illnesses in adults in three districts in Kenya
with differing malaria endemicity.
Results: A total of 12, 445 households were visited and data collected on recent illnesses in 11, 505 children and 19,
914 adults. OTC medicines were the most popular first response to fever in children with fever (47.0%; 95% CI 45.5,
48.5) and adults with acute illnesses (56.8%; 95% CI 55.2, 58.3). 36.9% (95% CI 34.7, 39.2) adults and 22.7% (95% CI 20.9,
24.6) children using OTC medicines purchased antimalarials, with similar proportions in low and high endemicity districts.
1.9% (95% CI 0.8, 4.2) adults and 12.1% (95% CI 16.3,34.2) children used multidose antimalarials appropriately. Although
the majority of children and adults sought no further treatment, self-referral to a health facility within 72 hours of illness
onset was the commonest pattern amongst those seeking further help.
Conclusion: In these surveys, OTC medicines were popular first treatments for fever in children or acute illnesses in
adults. The proportions using OTC antimalarials were similar in areas of high and low malaria endemicity. In all districts,
adults were more likely to self-treat with OTC antimalarial medicines than febrile children were to receive them, and
less likely to use them in recommended ways. Government health centres were the most common second resort for
treatment and were often used within 72 hours. In view of these practices, more research is needed to assess the impact
on the popularity of private medicine sellers of strengthened public sector policies on access to malaria treatment and
insecticide-treated bed nets. Improved targeting of OTC antimalarials to high risk groups, better communication
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strategies regarding adult as well as children's dosages, and facilitating more rapid referral to trained health workers
where needed are important challenges to private medicine seller programmes.
Background
Malaria continues to be a major cause of death and disa-
bility [1] and contributes to economic weaknesses in poor
countries [2] despite increased international support for,
and coordination of, research and control efforts [3,4].
Insecticide-treated bed nets (ITNs) and intermittent pre-
sumptive treatment of malaria in pregnant women and
infants have been shown to be successful control meas-
ures, and research on malaria vaccines holds promise for
the future [4-7]. However, the availability of prompt effec-
tive treatment of clinical malaria will remain a fundamen-
tal control mechanism either alone or alongside
additional measures, where these can be effectively imple-
mented [4]. There are macroeconomic and political chal-
lenges in ensuring that effective antimalarial medicines
are available through the public sector at country level [8-
10]. In Kenya, for example, implementation of antimalar-
ial drug policy changes in 2005 occurred more than 32
months after the initial decision, as a result of complex
financing and procurement systems and prolonged nego-
tiations with the pharmaceutical industry [11]. Socio-eco-
nomic and geographic barriers to treatment through
government clinics and hospitals has led to a proliferation
of untrained private medicine sellers in many settings
[12]. In recognition of the latter phenomenon and the
problems associated with practices in this sector, interna-
tional and national malaria control strategies have identi-
fied private medicine sellers as an important target to
promote appropriate home treatment [13,14].
Since 2001, the Kenya National Malaria Strategy (KNMS)
has supported the implementation of programmes target-
ing private sellers of OTC medicines and their clients
within district malaria control activities [14]. Thirty-three
districts have obtained support to implement educational
programmes for medicine sellers and communities on the
use of antimalarial medicines in the home from the Glo-
bal Fund to fight AIDS, Tuberculosis and Malaria
(GFATM). In April 2004, Kenya changed the first-line rec-
ommended antimalarial drug policy from Sulphadoxine/
Sulphalene-pyrimethamine medicines (SP) to the arte-
mesinin-based combination therapies (ACT), with a
phased introduction through the formal government and
mission sectors, to be followed by the private formal sec-
tor. The policy proposed ultimate inclusion of private
medicine sellers, depending on early experiences with the
change [15].
In this paper, we present data from household surveys of
treatment seeking behaviour for recent childhood fevers
and adult illnesses, and on malaria prevalence in well
children under five years, in rural areas of three districts in
Kenya. The data were collected during surveys conducted
collaboratively by the Kenyan Medical Research Institute
(KEMRI) Wellcome Trust Research Programme and the
Division of Malaria Control (DOMC) in the Kenyan Min-
istry of Health (MOH) in 2002 and 2003 in districts with
varying malaria transmission. The surveys aimed to
inform the planning and evaluation of district-led train-
ing programmes for private medicine retailers and com-
munities on malaria and its treatment. Data from the
malaria parasite prevalence surveys are presented in this
paper as markers for transmission pressure in the study
sites, and for comparison with treatment-seeking behav-
ior patterns. The findings are discussed with particular
emphasis on adult OTC antimalarial use as an emerging
challenge to programmes addressing this sector.
Methods
Study sites and population
The Kenya DOMC selected three districts for study, Busia,
Makueni and Kwale (Figure 1). Two districts (Kwale and
Makueni) had already been identified as sentinel districts
for the monitoring and evaluation of targets set in the
KNMS, such as access to antimalarial drugs and coverage
of ITNs [14]. Kwale (population 544,468) is a coastal dis-
trict with high perennial malaria transmission, while
Makueni (population 771,545) is a semi-arid area with
seasonal transmission located midway between Nairobi
and the coast. Busia (population 405,389) was chosen as
a site of high perennial malaria transmission in Western
Kenya. Within these districts, surveys were conducted in
divisions identified by health management teams as
potential sites for future retailer programmes. The divi-
sions selected were all considered to have similar malaria
incidence rates (from routine Health Information System
data) and to contain typical remote rural areas. Priority
was given to areas without existing governmental or non-
governmental community based malaria control pro-
grammes. Ten study divisions were chosen in consultation
with district health teams for random allocation to inter-
vention (for early implementation) and control (for later
implementation); two in Busia and four each in Kwale
and Makueni. Table 1 describes the population and gov-
ernment health facilities within the study divisions.
Study design and method
This was a descriptive study based on cluster randomized
cross sectional household surveys conducted during the
peak malaria transmission season in each district. TheMalaria Journal 2007, 6:57 http://www.malariajournal.com/content/6/1/57
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methods used were surveys of reported treatment seeking
behaviour for recent illness episodes in young children
and adults, and malaria parasite prevalence surveys in a
sub sample of well children using rapid diagnostic tests.
Household surveys
In each study division, a list of National Census enumer-
ation areas was used to construct a sampling frame and
units for the household survey. Since some enumeration
areas were much larger than others, to avoid weighting the
chances of selection by population size, those with greater
than 110 households were subdivided into smaller units
prior to randomisation. In each district, a total of 4,000
households were identified in randomly selected enumer-
ation areas (or subdivisions) of approximately 100 house-
holds. The sample size calculation was derived for
planned future evaluations of the retailer training pro-
grammes, with a primary outcome of the proportion of
childhood fevers treated with OTC antimalarials that
included an adequate amount of the MOH recommended
treatment. Since the future evaluations planned to include
both intra and inter-district comparisons, sample sizes for
the current household survey were calculated around
comparisons of these proportions within districts, provid-
ing standard errors of 1.6% and 2.2% around estimations
of 10% and 20% respectively (coefficient of variation 0.2)
[16].
Locally recruited and trained field workers collected
detailed information on treatment seeking behaviour for
children under five years of age with a recent fever and for
adults present in the household at the time of interview
with a recent acute illness, using a structured question-
naire. Recent episodes were defined as those occurring
within a two-week period of the interview. In this survey,
two target age groups were identified; children under five
who present the greatest vulnerability to severe disease,
and individuals over the age of fourteen years, as an adult
group likely to make an autonomous decision on treat-
ment seeking. To counteract the potential for reporting
bias, a pre-tested questionnaire developed and validated
from previous studies was used [17], and field workers
used drug charts containing samples of commonly used
OTC medicines to aid recall and validate reports, and
remaining packages or tablets were reviewed where possi-
ble. Data were checked for inaccuracies and inconsisten-
cies daily before double entry and verification using
FOXPRO version 6 (Microsoft Corp, Redmond, WA,
USA). Adjustment was made for clustering at EA level
using Svy data commands in STATA version 8 (Stata Corp,
College Station, Texas, USA). Proportions for key out-
comes are presented with 95% confidence intervals. Chi-
square tests of association were used to compare propor-
tions across the districts and analysis of variance
(ANOVA) models were used to compare means. Since one
of the most common OTC antimalarial medicines in use,
amodiaquine (AQ), has a three-day regime of administra-
tion, episodes where treatment was started within three
days of the interview were excluded.
Malaria parasite prevalence surveys
Randomly identified sub-samples of 971, 963 and 980
children from the household survey in Busia, Kwale and
Makueni districts, respectively, were invited to participate
Table 1: Population and number of health facilities in study divisions
Division Population* Number of government health centres Number of government dispensaries Number of private pharmacies
Makueni district
Kathonzweni 65,738 2 5 2
Kalawa 26,333 1 2 2
Matiliku 38,867 2 2 4
Makindu 50,299 1 3 3
Kwale district
Matuga 78,814 1 6 1
Kinango 78,433 0 7 2
Msambweni 230,648 3 20 4
Samburu 99,105 2 8 2
Busia district
Matayos 60,365 1 2 3
Butula 104,450 2 1 11
*From National Census Data [46]Malaria Journal 2007, 6:57 http://www.malariajournal.com/content/6/1/57
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A map of Kenya showing the geographical locations of the three districts included in this study Figure 1
A map of Kenya showing the geographical locations of the three districts included in this study.Malaria Journal 2007, 6:57 http://www.malariajournal.com/content/6/1/57
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in a cross sectional survey of malaria parasite and anaemia
prevalence. The prevalence of anaemia was assessed dur-
ing the baseline as a marker for programme impact in the
future, and data on haemoglobin concentrations are not
presented in this paper. The sample size was based on a
conservative estimate of 50% prevalence for moderately
severe anaemia [18], with a confidence interval of 44% –
56%. Participants were screened at temporary local cent-
ers using rapid diagnostic tests for malaria (Uni-Gold ™
Trinity Biotech, Ireland). Children with parasitaemia and
a history of fever and those with anaemia were provided
with treatment in accordance with a treatment protocol
approved by the national Scientific Coordinating Com-
mittee and the District Medical Officer of Health.
Ethical approval
The Kenya National Scientific Steering and Ethical Com-
mittees and World Health Organization Ethics Review
Committee granted approval for the study. The aim and
purpose of all components of the study was discussed and
agreed with local leaders. Verbal informed consent was
sought for the household survey and information sheets
including contact details were left in each home visited.
Signed informed consent was obtained from parents or
guardians for the malaria parasite prevalence survey.
Reports on the findings of the surveys were sent to District
Health Management Teams.
Results
12,445 households were visited to interview 11,505 car-
egivers of children under five years and 19,914 adults
across all the districts. Table 2 summarizes the number of
households visited, interviews held, the prevalence of
recent fevers in children or acute illnesses in adults, pat-
terns of OTC medicines use in children and adults and
parasite prevalence in each district. Parasite prevalence in
Makueni was compatible with a hypoendemic pattern of
malaria transmission, in contrast to the hyperendemic
patterns seen in Kwale and Busia [19]. OTC medicines
provided the commonest first treatment for fevers in chil-
dren and acute illness episodes in adults. In general, chil-
dren with fever treated through private retailers were more
likely to be given an antipyretic than an antimalarial treat-
ment, especially in Kwale and Makueni. Adults were more
likely to buy antimalarials to treat their own illnesses than
children were to receive these for febrile illnesses. The two
most commonly used types of OTC antimalarials were the
MOH first and second line recommended medicines at
that time, SP and AQ, respectively, together accounting for
80.1% (95% CI 76.4, 83.3%) and 86.4% (95% CI 83.9,
83.3%) of all OTC antimalarials used in children and
adults respectively. The remaining 19.9% of antimalarials
used in children included chloroquine (16.6%), combi-
nations of AQ and SP (2.1%) and others (1.3%). Among
adults the remaining 13.6% of antimalarials included
chloroquine (10.0%), combinations of AQ and SP
(2.8%), and others (0.6%). The first line recommended
medicine, SP, was more commonly used than AQ in one
district for children (Busia, where 46.0% children using
OTC AMs received SP) but in all other areas and age
groups, AQ was either more likely or equally likely to be
used. The adequacy of treatment was gauged in compari-
son to the national malaria guidelines on AM medicine
use, shown in tables 3 and 4. Across all districts, single
dose SP was used adequately by the majority (83.8%; 95%
CI 78.7, 86.6) of adults and by nearly half (46.4%; 95%
CI 39.5, 53.4) of children. Multiple dose AQ medicines
were generally used inappropriately; 12.1% children
(95% CI 16.3, 34.2) and 1.9% adults (95% CI 0.8, 4.2)
took adequate amounts of AQ for their illness. The com-
mon pattern reported for AQ was single dose treatment.
Table 5 presents data on the second actions taken by those
who used OTC medicines as a first step. For this analysis,
users who purchased medicines more than once from a
shop before moving to a second resort to treatment were
grouped as single action. 82.9% children and 88.9%
adults using OTC medicines as a first measure took no fur-
ther action. Amongst the group taking no further action,
9.7% children (133/1377) and 13.5% adults (209/1547)
reported remaining unwell, while the remainder reported
full or almost complete recovery (where the latter was
defined as having no intention to seek further treatment).
For the minority that took further action, most subse-
quently visited a formal provider but this action was gen-
erally not taken within 48 hours of onset of illness.
However, by 72 hours, 66.9% (95% CI 61.1, 72.3) of chil-
dren in this group of self-referrals reported consultation at
a government or private clinic.
Discussion
Given the high global burden of young childhood disease
and deaths attributed to malaria [1,2], early effective treat-
ment of childhood fevers has become a main focus within
global and national malaria control strategies [3,13,14].
Such strategies highlight the role of private medicine
retailers to promote early effective home treatment of
childhood malaria in endemic settings [13]. More
recently, the introduction of ACTs as first line treatment
for malaria in many countries in sub Saharan Africa has
led to debate on the role of community-based mecha-
nisms for delivery of malaria treatments [20-23]. Under-
standing patterns of OTC medicine use is important to
assess the opportunities and challenges of programmes
for private medicine retailers, but there is limited detailed
data on adult OTC antimalarial use in the literature [23-
26]. This study reports on patterns of OTC medicines use
from large-scale surveys including child and adult popula-
tions across three districts in Kenya with varying malaria
endemicity.Malaria Journal 2007, 6:57 http://www.malariajournal.com/content/6/1/57
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In interpreting these results, it is important to consider
limitations of the study methods. The data on treatment
seeking behaviour were collected from reports concerning
recent illness episodes. While standard practices were used
to ensure that these were as accurate as possible (careful
training and supervision of interviewers, internal validity
checks in questionnaires, use of locally constructed drug
charts with packaging and logo visuals to aid recognition,
and inspection of left-over tablets), this type of data is
always open to recall and reporting biases. In the house-
hold survey, for pragmatic reasons, histories were elicited
for all children within a household who met inclusion cri-
teria for age, including siblings. Theoretically, this may
lead to clustering of data within households for which no
allowance has been made in the analysis. Confidence
intervals could therefore be wider than those stated here,
although these are generally small given the size of these
surveys. There is some evidence that intra-household clus-
tering would have a negligible effect; a study in rural Tan-
zania found no difference in the outcome of an analysis of
treatment seeking behaviour for all young children and
for only one randomly selected child within that house-
hold [27]. Finally, these data were collected from surveys
conducted in 2002 and 2003, at a time when the recom-
mended first line antimalarial medicine in Kenya was SP.
Practices of drug use may have changed over time, and
care should be taken in extrapolating these results to
understand use of other antimalarial medicines. However,
Table 2: Number of households visited, prevalence of illnesses, use of OTC antimalarials and malaria parasite prevalence (%: 95% CI)
Busia Kwale Makueni All districts P values *
Households visited 4017 4174 4254 12 445 -
Children under 5 years
Number interviewed 3451 4081 3973 11 505 -
Recent fever 1437/3451
(41.7: 39.5, 43.9)
1770/4081
(43.3: 41.5, 45.2)
1216/3973
(30.8: 28.7, 33.0)
4423/11 505
(29.0: 28.1, 29.8)
<0.001
Fevers first treated with OTC medicines† 540/1437
(37.6: 35.1, 40.1)
898/1770
(50.7: 48.3, 53.1)
641/1216
(52.7: 49.8, 55.5)
2079/4423
(47.0: 45.5, 48.5)
<0.001
OTC users taking an AM‡ 237/519
(45.7: 41.3, 50.1)
147/898
(16.3: 13.9, 18.9)
83/638
(13.3: 9.5, 17.9)
467/2057
(22.7: 20.9, 24.6)
<0.001
OTC SP users taking adequate dose§ 68/141
(48.3: 37.9, 58.8)
19/39
(48.6: 32.5, 64.9)
11/31
(40.4: 19.0, 66.3)
98/211
(46.4: 39.5, 53.4)
0.415
OTC AQ users taking adequate dose 16/112
(14.2: 8.7, 22.2)
5/56
(9.1: 4.0, 19.5)
3/31
(10.7: 3.4, 28.9)
24/98
(12.1: 16.3, 34.2)
0.547
Rapid malaria test positive 805/971
(82.8: 79.0, 86.1)
695/963
(71.1: 64.4, 76.9)
34/980
(3.2: 2.1, 4.8)
1534/2914
(52.6: 50.8, 54.4)
<0.001
Adults
Number Interviewed|| 6198 6750 6966 19 914 -
Recent illness** 1027/6198
(16.6: 14.4, 19.0)
1805/6750
(26.7: 24.9, 28.6)
1268/6966
(18.2: 17.1, 19.4)
4098/19 914
(20.6: 20.0, 21.1)
<0.001
First treated with OTC medicines 472/1027
(46.0: 42.8, 49.1)
1103/1805
(61.1: 58.8, 63.3)
753/126510
(59.5: 56.7, 62.2)
2328/4097
(56.8: 55.2, 58.3)
<0.001
OTC users taking an AM Not collected†† 291/1081
(26.9: 21.3, 33.5)
384/745
(53.3: 48.6, 57.9)
675/1826
(36.9: 34.7, 39.2)
<0.001
OTC SP users taking adequate dose 80/102
(78.3: 68.4, 85.8)
75/95
(79.4: 68.3, 87.3)
157/179
(87.7: 81.5, 92.0)
312/376
(83.8: 78.7, 86.6)
0.07
OTC AQ users taking adequate dose 2/44
(4.4: 1.1, 16.6)
0/148 5/174
(2.4: 0.9, 6.0)
7/336
(1.9: 0.8, 4.2)
0.07
*. Chi-square test of association for differences between districts
†. Includes episodes where the individual was visited 3 days or more after treatment begun to exclude part courses of amodioquine (also see 
methods); OTC medicines includes those bought from general shops, chemists or mobile vendors and those kept at home from. 2. All adults 
available in the home at the time of visit
‡ There were 21 episodes in Busia and 3 in Makueni where OTC medicine could not be identified
§. Adequate dosage is according to MOH recommendations (see table 3 and 4): over dosage occurs when more and under dosage when less than 
the recommended amount of the drug is given
|| All adults available in the home at the time of visit
**. In Busia, the frequency refers to the number of adults reported "perceived malaria" whereas in Kwale and Makueni this represents the number 
of adults with a recent acute illness of any type, excluding trauma.
†† Data on the proportion of acute illnesses in adults where an AM was used was not collected in Busia.Malaria Journal 2007, 6:57 http://www.malariajournal.com/content/6/1/57
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the pattern of poor adherence with multidose medicines
is not a new or isolated phenomenon [28,29] and many
factors underlying medicine use for acute illnesses (cost,
complexity of regimen and rate of response) are likely to
be generalisable.
The data presented here concur with earlier descriptions
of the popularity of private medicine sellers as an early
treatment option for childhood fevers, and the inappro-
priate ways in which OTC antimalarial medicines are gen-
erally used in young children [17,23,30-33]. The study
further illustrates that adults with a recent acute illness
were more likely to use an antimalarial medicine than
were young children to receive them for a febrile illness,
even in hypoendemic districts. These findings reinforce
the need to intervene in a sector that is chaotic but poten-
tially offers an opportunity to improve early fever treat-
ment practices in children. They also point to
shortcomings in applying current global home malaria
management strategies that focus primarily on young chil-
dren to private retail sector interventions. While the under
five age group experiences the greatest burden of malaria
disease in endemic settings, adult use of OTC antimalar-
ials may represent a greater challenge to strategies to opti-
mise their use [34].
There is limited information on adult use of OTC antima-
larial medicines. Several studies have addressed the fre-
quency of OTC antimalarial use in adult populations in
specific settings, but there is less information on the way
that these medicines are used, or from large-scale surveys
in areas of varying malaria endemicity. A study of OTC
antimalarial use in a highland area of low seasonal
malaria transmission in Kenya described a similar excess
of adult over paediatric use (24% of adult and 14% of
child OTC users purchased an antimalarial) [24]. High
use of OTC antimalarials has been described for older
school children in Kenya [26], as have similarities
between adult and child use of OTC antipyretic and anti-
malarial medicines in a qualitative study in Ghana [25].
Adult over-use of antimalarials is an important phenome-
non because of the potential for wastage of resources
where adults have a lower risk of malaria than children.
The extent of over-use is highlighted by the popularity of
these medicines even in areas with low and seasonal
malaria transmission. Adult over-use affects estimations
of the volume of malaria medicines used in the private
retail sector and therefore has an economic implication
for governments and households, particularly in anticipa-
tion of, or following, the introduction of ACTs [24]. There
may be an impact of under dosing on the development of
drug resistance. Although the relationship between these
is not straightforward, resistance is likely to be selected for
where partially effective treatments result in recrudescence
of infection [35]. If under dosing contributes to increased
Table 4: National guidelines on dosage by age for AQ medicines. [1 tab = 200 mg AQ base; 5 ml = 50 mg AQ base]
Total no spoons syrup
Age Days given over Total no tabs Total in mg tsp (5 ml) tbs (10 ml)
< 6 months 3 3/4 – 1 150 – 200 3 – 4 1/2 1 1/2 – 2
6 – 11 months 3 1 1/4 – 1 3/4 250 – 350 5 – 7 1/2 2 1/2 – 3 1/2
12 – 47 months 3 2 – 2 1/4 400 – 450 7 1/2 – 9 1/2 4 – 5
48 – 71 months 3 2 1/2 – 3 1/2 500 – 700 10 – 14 1/2 5 – 7
15 – 16 years 3 4–6 1/4 800–1250 - -
16 + years 3 6 1/2–7 1/2 - 1300–1500 - -
Table 3: National guidelines on dosage by age for SP medicines. [1 tab = 500 mg sulphadoxine, 25 mg pyrimethamine; 5 ml = 250 mg 
sulphadoxine, 12.5 mg pyrimethamine]
Total no spoons syrup
Age Days given over Total no tabs Total in mg* tsp (5 ml) tbs (10 ml)
<11 months 1 1/2 – 3/4 250 – 375 1 – 1 1/2 1/2 – 3/4
12 – 59 months 1 1 – 1 1/4 500 – 625 2 – 2 1/2 1 – 1 1/4
5–8 years 1 1 1/2 – 1 3/4 750–875
9–14 years 1 2–2 3/4 1000–1375
15+ years 1 3 1500 - -
*for sulpha componentMalaria Journal 2007, 6:57 http://www.malariajournal.com/content/6/1/57
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resistance of malaria parasites to antimalarial medicines,
the widespread existence of such practices amongst adults
as well as children can only increase this effect.
For both adults and children, there are clear differences in
adherence to SP and AQ medicines, with adherence to SP
being much higher than AQ. This finding is likely to be a
result of the different regimes for administration, with SP
medicines being given in a single dose in contrast to the 3-
day AQ regimen. There is evidence that other multiple
dose medicines, such as chloroquine, have commonly
been used as single doses in the past, including in Kenya
[36]. Adherence to multidose ACTs may present a similar
problem, particularly given the speed of response of
symptoms, such as fever, to this group of medicines.
Although high adherence to ACTs has been documented
in the formal sector [37,38], under-dosing is often a cost-
saving strategy [32,39] and is, therefore, particularly likely
to affect private retail sector treatments where the costs are
directly related to the quantity of medicine obtained. This
incentive to cut down on full courses of medicines may
plausibly be greater for adults than for young children in
keeping with the larger amounts of medication that they
require. In this survey, adult AQ adherence is considerably
worse than that reported for children.
A further pattern of interest emerging from the study con-
cerns movement between private medicine sellers and
trained health workers. Amongst the minority (14.4%),
who sought further treatment after using OTC medicines,
most carers (approximately 84%) chose to visit a trained
health worker. Self referral to such a facility did not gener-
ally occur within 24 hours of onset of illness, as recom-
mended by the Roll Back Malaria initiative [13], but the
majority did seek further assistance by 72 hours. Kemble
et al studied this pattern of self referral in an urban popu-
lation in Kampala, finding a much higher proportion
(42%) of child OTC users were subsequently taken to a
formal provider, although with similar timing [23]. In an
epidemic area in Uganda, health facilities were reported as
the commonest first line treatment for both adults and
children with suspected malaria [40]. More research on
these patterns, and the factors underlying self-referral
behaviour would help to elucidate opportunities for opti-
mising these practices.
Programmes for private medicine retailers in malaria con-
trol have been based on pragmatic principles, and these
still obtain. The challenges of working with informal pri-
vate providers have been well articulated at the policy
level, including the size of the sector in many countries,
lack of regulatory mechanisms and capacity, lack of organ-
izational structures, multiplicity of brands, inadequate
quality of OTC medicines, difficulties in diagnosing
malaria clinically and commercial interests of retailers
[5,12,20,41,42]. However, unit dose pre-packaging inter-
ventions have already been shown to improve adherence
with multidose medicines, and may prove effective for
Table 5: Actions following first use of OTC medicines (%: 95% CI)
Busia Kwale Makueni Overall P
Children
No further action after OTC 511/540
(94.6)
(92.3, 96.6)
657/837
(77.9)
(73.3, 82.0)
469/598
(78.3)
(73.4, 82.6)
1637/1975
(82.9)
(81.1, 84.5)
<0.001
2nd action is use of clinic 24/540
(4.4)
(2.8, 6.5)
153/837
(18.3)
(15.7, 21.1)
107/598
(17.9)
(14.9, 21.2)
284/1975
(14.4)
(12.8, 16.0)
<0.001
Visits clinic within 48 h* 8/24
(33.3)
(15.6, 55.3)
37/153
(24.2)
(17.6, 31.7)
41/107
(38.3)
(29.1, 48.2)
86/284
(30.3)
(24.9, 35.9)
0.05
Adults
No further action after OTC : 427/453
(94.3)
(91.7, 96.2)
923/1065
(86.4)
(83.1, 89.0)
637/717
(88.6)
(85.6, 91.0)
1987/2235
(88.9)
(87.5, 90.1)
<0.001
2nd action is use of clinic : 4/453
(0.9)
(0.2, 2.2)
104/1065
(9.8)
(8.0, 11.7)
63/717
(8.8)
(6.8, 11.1)
171/2235
(7.7)
(6.5, 8.8)
<0.001
Visits clinic within 48 h 3/4
(75.0)
(19.4,99.3)
32/104
(30.1)
(22.1, 40.6)
11/63
(17.5)
(9.0, 29.1)
46/171
(26.9)
(20.4, 34.2
0.015
*. Within 48 hours of the onset of the illnessMalaria Journal 2007, 6:57 http://www.malariajournal.com/content/6/1/57
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antimalarial medicines in the private retail sector (10, 41).
The opportunities provided by this sector have also
proved compelling, including sustainability, cost and cov-
erage [31,36,43,44], particularly given the shortcomings
reported in the public sector, reviewed recently by Zuro-
vac and Rowe [45]. Mills et al illustrate this pragmatism
writing that "...training and investment in formal sector
providers (public and private) and restructuring of the
market so as to strengthen the purchasing and regulation
functions of government, may displace the informal sec-
tor, but this is likely to be a very long term process" [12].
The data presented in this paper show that the group of
mothers who visit a health facility as a second option is a
minority, but that this self-referral occurs relatively
quickly, even in rural settings. Kemble suggests that faster
movement to a health centre may be achievable with the
provision of adequate, acceptable and affordable services
and a better public understanding of the need for rapid
treatment of childhood fevers [23]. This data also indicate
that interventions directed at increasing usage of health
facilities may be feasible and play an important part in
improving early effective malaria treatment. With recent
increased investment in malaria control activities, further
research is needed to establish the extent to which the
introduction of free, effective antimalarial treatment in
government health facilities, and the wider availability of
free or affordable ITNs can influence the balance of choice
for users between trained public and untrained commer-
cial providers in the future, taking account of socio-eco-
nomic and geographic differences. Where OTC
antimalarial use remains a popular option, greater target-
ing of antimalarial medicines to high risk populations,
and away from the current predominantly adult market,
will be an important challenge for private medicine
retailer programmes in the future [12,23,24].
Conclusion
The findings of this survey across three districts of differ-
ing malaria endemicity in Kenya confirm the common use
of OTC medicines for fever in children and acute illnesses
in adults, as well as the widespread inappropriate use of
these medicines. They point to the frequent use of OTC
antimalarial medicines in adults, irrespective of disease
transmission rates, and the high risk that this will be
accompanied by under dosing. A minority of OTC users
subsequently seek further treatment through the formal
sector, but many of these self-referrals occur within 72
hours of onset of illness even in rural situations. More
research is needed to assess the impact on the popularity
of private medicine sellers of free malaria treatment in
public health facilities for children under five years and
increased community coverage with treated bed nets.
Improved targeting of OTC antimalarial medicines to
high risk groups, better communication strategies on
adult as well as children's dosages, and facilitating appro-
priate referral to trained health workers are important
challenges to private medicine seller programmes.
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